Kidney Donor Outcomes Cohort (KDOC) Study



Status:Completed
Healthy:No
Age Range:18 - Any
Updated:4/17/2018
Start Date:August 2011
End Date:February 2018

Use our guide to learn which trials are right for you!

Live donor kidney transplantation (LDKT) is important because its outcomes for recipients are
superior to those of deceased donor transplantation, and it yields significant cost savings
to the healthcare system overall. Despite efforts over the past few decades to enhance
understanding of the short- and long-term outcomes of living kidney donation, it is clear
that investigators have more knowledge in some areas (e.g., surgical and medical
complications) than in others (e.g., psychological outcomes, financial impact). While the
transplant community and changes in federal regulations have brought attention to the need
for more systematic study of living donor outcomes, there remains a paucity of scientifically
rigorous multisite, prospective outcome studies. The long-term goal of this research program
is to characterize the short- and long-term surgical, medical, functional, psychological, and
financial outcomes of living kidney donation. The objective of this study is to establish a
multisite prospective cohort of living kidney donors, their recipients, and a healthy
comparison group. This cohort will be used to examine three primary aims: (1) to assess donor
outcomes (surgical, medical, functional, psychological, financial) over a 2-year period
initially, with the intention of examining these outcomes over a more extended time period in
subsequent years; (2) to identify the donor, recipient, and center variables that are most
predictive of donor outcomes; and (3) to identify disparities in donor outcomes and their
predictors. To accomplish these aims, six kidney transplant programs, representing six states
(Massachusetts, Maine, Rhode Island, New York, Iowa, and Arizona) and with experience and
expertise in caring for living donors and transplant recipients, will participate in the
study. Donors, their recipients, and healthy controls will complete comprehensive assessments
at baseline (pre-surgery) and at 1, 6, 12, and 24 months post-donation. This study will
extend the investigators considerable preliminary work by simultaneously examining outcomes
that are of importance to donors, recipients, healthcare providers, and policymakers. The
rationale for this research is that, once these outcomes and their predictors are known,
investigators can further develop and refine educational strategies and informed consent
processes for both living donors and their intended recipients, as well as provide systematic
data to inform policy discussions and clinical care practice.

Kidney transplantation extends and improves the lives of adults with end-stage renal disease
(ESRD). Live donor kidney transplantation (LDKT) has many advantages over deceased donor
transplantation for the recipient, including shorter or no dialysis exposure, immediate graft
function, lower perioperative morbidity and mortality, and better long-term graft and patient
survival. Also, it yields significant cost savings to the healthcare system overall. These
relative advantages and other advances in the field (e.g., laparoscopic techniques, paired
kidney exchanges) have led transplant candidates and programs to more proactively embrace
LDKT as the primary treatment option. Living kidney donors now account for 40% of all kidney
transplants performed in the United States during the past 10 years, and more than 90,000
adults have undergone living donor nephrectomy in the United States over the last 20 years.

Worldwide there have been few large-scale studies examining the short- and long-term outcomes
of living kidney donation, and many have been limited by retrospective, cross-sectional,
and/or single-center designs with no appropriate control group. Despite efforts to enhance
understanding of donor outcomes, it is clear that we have more knowledge in some areas (e.g.,
surgical and short-term medical complications) than in others (e.g., long-term medical
complications, psychological outcomes, financial impact). The relative paucity of multisite,
prospective outcome studies is concerning, especially considering the expanding donor
eligibility criteria used by transplant programs today. Over the past decade, criteria for
acceptance of a living donor candidate has changed: some donor candidates who would not have
been considered 15 years ago (e.g., those with hypertension, obesity, or no prior
relationship with the recipient) are now readily evaluated by many programs.

Recently, the transplant community and changes in federal regulations have brought attention
to the need for more systematic study of living donor outcomes. While reporting outcomes over
a 2-yr period is now mandated by the Organ Procurement and Transplantation Network (OPTN) and
the United Network for Organ Sharing (UNOS), most transplant programs do not systematically
collect donor outcome data. The lack of such data is an important problem because, without
it, we will continue to have considerable variability in informed consent processes for
living donors and their recipients, as well as limited data to inform clinical practice and
policy development. This study directly addresses several of the recommendations made by the
U.S. Department of Health and Human Services' Advisory Committee on Organ Transplantation.

A. Design Overview

This is a six center, prospective observational cohort study. A total of 280 living kidney
donors, 280 LDKT recipients, and 160 healthy comparison subjects meeting all eligibility
criteria will be enrolled. Participants will complete the assessment protocol at 5 time
points: prior to surgery (Baseline, T1), 1 month after surgery (T2), 6 months after surgery
(T3), 12 months after surgery (T4), and 24 months after surgery (T5). The rationale for
selecting these time points is that they correspond to the assessment intervals currently
required by the OPTN/UNOS for living donor follow-up, which were selected by the Living
Donation Committee as the most appropriate time points for gathering short- and long-term
follow-up data.

B. Study Participants

A total of 280 living kidney donors, 280 LDKT recipients, and 160 healthy comparison subjects
meeting all eligibility criteria will be enrolled.

We will enroll both English and Spanish speaking participants into the study. All
questionnaire outcomes will be translated into Spanish using conventional translational
procedures and we will ensure that an interviewer at BIDMC is fluent in Spanish. It is
important to emphasize that not all of the questionnaires used in this study have been
validated in Spanish or with Hispanic patients. While this is an important limitation, we
feel that this limitation is outweighed by the potential benefits of including primarily
Spanish-speaking participants in the study.

The primary focus of the study is on assessing donor outcomes. The rationale for including
the recipient is to examine the role that recipient factors play in predicting donor
outcomes. There is preliminary evidence that some aspects of the recipient's functioning
(e.g., graft survival, QOL) are associated with certain functional and psychological outcomes
in living donors.7,8,88 The inclusion of transplant recipients in the study permits further
examination of this association over time and allows us to include other recipient variables
that heretofore have been neglected (e.g., perceptions of the donor-recipient relationship).
Also, we will recruit a healthy, non-donor comparison group. A healthy comparison group
allows us to address the question, "What if I had not donated my kidney?" - a question that
is often considered by donors. These will be adults who completed one or more parts of the
donor evaluation, but who did not proceed further for various reasons (although none of them
medical).

C. Participant Recruitment and Retention

The first participant will be enrolled into the study in September 2011. Recruitment time is
scheduled for 24 months. The last study assessment, therefore, will be completed in August
2015. Target recruitment for each site is 47 donor-recipient pairs and 27 healthy
comparisons.

Importantly, we will recruit living donors into the study regardless of their recipient's
participation status. Even in the absence of the recipient's participation, we will obtain
valuable data about donor outcomes. However, because this is first-and-foremost a study
evaluating donor outcomes, if a donor does not consent to participate in the study, we will
not approach their recipient about study participation.

Non-directed donors will be recruited into the study. If it's an anonymous donation, their
recipient will not be approached about the study. In the case, only the donor will be
enrolled. If the non-directed donor has established a relationship (albeit a new one) with
the intended recipient, then we will attempt to enroll both the donor and the recipient into
the study, just like any other donor-recipient pair.

Donors participating in a paired kidney donation program (KPD) will be recruited into the
study. In this instance, we will enroll KPD donors and their intended recipient (i.e., the
recipient with whom they are incompatible, not the recipient of their specific kidney).

For each transplant recipient enrolled in the study, we will determine if s/he had other
potential donors who were initially screened or evaluated but who did not progress to
donation surgery. This initial screening or evaluation may include an initial health history,
ABO testing, and/or other preliminary tests. To qualify as a control subject, the non-donor
may or may not have completed the entire evaluation, but none of the studies performed will
have excluded them from donation. If an enrolled donor has more than one potential health
control subject, we will attempt to recruit them all into the study.

Inclusion Criteria:

- at least 18 years old

- residential or cell phone service

- written informed consent

- medically cleared for donor nephrectomy (donor)

- medically cleared for transplant surgery (recipient)

- did not progress to donation, although medically eligible (control)

- completed preliminary labs (control)

Exclusion Criteria:

- inability or unwillingness to provide informed consent

- inability to speak and read English or Spanish
We found this trial at
7
sites
3550 Jerome Avenue
Bronx, New York 10467
(718) 920-4321
Montefiore Medical Center As the academic medical center and University Hospital for Albert Einstein College...
?
mi
from
Bronx, NY
Click here to add this to my saved trials
330 Brookline Ave
Boston, Massachusetts 02215
617-667-7000
Beth Israel Deaconess Medical Center Beth Israel Deaconess Medical Center (BIDMC) is one of the...
?
mi
from
Boston, MA
Click here to add this to my saved trials
9500 Euclid Avenue
Cleveland, Ohio 44106
216.444.2200
Cleveland Clinic Cleveland Clinic is committed to principles as presented in the United Nations Global...
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
101 Jessup Hall
Iowa City, Iowa 52242
(319) 335-3500
University of Iowa With just over 30,000 students, the University of Iowa is one of...
?
mi
from
Iowa City, IA
Click here to add this to my saved trials
22 Bramhall St
Portland, Maine 04102
(207) 662-0111
Maine Medical Center One of the country's consistently highest rated hospitals is right in your...
?
mi
from
Portland, ME
Click here to add this to my saved trials
593 Eddy Street
Providence, Rhode Island 02903
401-444-4000
Rhode Island Hospital Founded in 1863, Rhode Island Hospital in Providence, RI, is a private,...
?
mi
from
Providence, RI
Click here to add this to my saved trials
Tucson, Arizona 85721
(520) 621-2211
University of Arizona The University of Arizona is a premier, public research university. Established in...
?
mi
from
Tucson, AZ
Click here to add this to my saved trials